Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials
TG Nuehrenberg, W Hochholzer, K Mashayekhi… - Clinical Research in …, 2018 - Springer
Aims The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary
intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial …
intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial …
Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials
BACKGROUND: The benefit: risk profile of bivalirudin versus heparin anticoagulation in
patients with non–ST-segment–elevation myocardial infarction undergoing percutaneous …
patients with non–ST-segment–elevation myocardial infarction undergoing percutaneous …
Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis
PR Oli, DB Shrestha, J Shtembari… - Coronary Artery …, 2023 - journals.lww.com
Background The use of bivalirudin-based anticoagulation over heparin-based
anticoagulation for coronary percutaneous intervention has been debated for a long time …
anticoagulation for coronary percutaneous intervention has been debated for a long time …
Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease
M Nardin, M Verdoia, L Barbieri, G De Luca… - Platelets, 2019 - Taylor & Francis
Platelets represent one of the main actors involved in pathogenesis of coronary artery
disease (CAD). Mean platelet volume (MPV) has been proposed as marker of platelet …
disease (CAD). Mean platelet volume (MPV) has been proposed as marker of platelet …
Antithrombotika und Antihämorrhagika
L Hein, H Wille - Arzneiverordnungs-Report 2020, 2020 - Springer
Zusammenfassung Auf einen Blick Trend Die Gesamtverordnungen der
Thrombozytenaggregationshemmer sind 2019 gegenüber dem Vorjahr weitgehend …
Thrombozytenaggregationshemmer sind 2019 gegenüber dem Vorjahr weitgehend …
Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual …
E Kedhi, M Verdoia, H Suryapranata, S Damen… - Atherosclerosis, 2021 - Elsevier
Background and aims The impact of advanced age on the optimal duration of dual
antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing …
antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing …
Antithrombotika und Antihämorrhagika
H Wille - Arzneiverordnungs-Report 2021, 2021 - Springer
Zusammenfassung Auf einen Blick Trend Die Gesamtverordnungen der
Thrombozytenaggregationshemmer sind 2020 gegenüber dem Vorjahr minimal, die der …
Thrombozytenaggregationshemmer sind 2020 gegenüber dem Vorjahr minimal, die der …
[HTML][HTML] Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses
WB Hillegass, GS Bradford - Journal of Thoracic Disease, 2016 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016; 8 (9): E1034-E1040
jtd. amegroups. com routine IIb/IIIa use, acute (< 24 hours) stent thrombosis was …
jtd. amegroups. com routine IIb/IIIa use, acute (< 24 hours) stent thrombosis was …
Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world …
Y Hu, W Yao, D Jin, J Zhang, L Wang, R Zhang, J Xu… - Medicine, 2021 - journals.lww.com
The efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) has
always been a hot topic in perioperative antithrombotic therapy, but there are still some …
always been a hot topic in perioperative antithrombotic therapy, but there are still some …
Antithrombotische Therapie
H Wille - Arzneiverordnungs-Report 2023, 2024 - Springer
Zusammenfassung Auf einen Blick Trend Die Gesamtverordnungen der
Thrombozytenaggregationshemmer sind 2022 gegenüber dem Vorjahr gering gesunken …
Thrombozytenaggregationshemmer sind 2022 gegenüber dem Vorjahr gering gesunken …